The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial
Abstract
PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment. PATIENTS AND METHODS: In this double-blind, double-dummy, parallel-group study, postmenopausal patients were randomized to receive either an intramuscular injection of fulvestrant 250 mg once monthly or a daily oral dose of anastrozole 1 mg. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability. RESULTS: Patients (n = 400) were followed for a median period of 16.8 months. Fulvestrant was as effective as anastrozole in terms of TTP (hazard ratio, 0.92; 95.14% confidence interval [CI], 0.74 to 1.14; P = .43); median TTP was 5.4 months with fulvestrant and 3.4 months with anastrozole. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease ≥ 24 weeks) were 42.2% for fulvestrant and 36.1% for anastrozole (95% CI, −4.00% to 16.41%; P = .26). In responding patients, median DOR (from randomization to progression) was 19.0 months for fulvestrant and 10.8 months for anastrozole. Using all patients, DOR was significantly greater for fulvestrant compared with anastrozole; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated. CONCLUSION: Fulvestrant was at least as effective as anastrozole, with efficacy end points slightly favoring fulvestrant. Fulvestrant represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
(1991) · PubMed · Cited by 1,101
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Self-citationUse of tamoxifen for breast cancer: twenty-eight years later.
Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.513 · Cited by 413
Self-citationICI 182,780 (Faslodex?): Development of a novel, ?pure? antiestrogen
Howell, A., Osborne, C. K., Morris, C., & Wakeling, A. E. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6 · Cited by 408
Self-citationOsborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Self-citationResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
Howell, A., DeFriend, D. J., Blamey, R. W., Robertson, J. F., & Walton, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91156-1 · Cited by 349
Vogel, C. L., Shemano, I., Schoenfelder, J. R., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.345 · Cited by 114
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Self-citationDi Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Metadata
- Authors
- Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., & Buzdar, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-15
- Volume
- 20
- Issue
- 16
- Pages
- 3386-3395
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139726760
- Cited by
- 642
- References
- 12
- FWCI
- 37.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.